KR20150129344A - Anti-obese and anti-diabetic composition comprising fingerroot polysaccharides - Google Patents
Anti-obese and anti-diabetic composition comprising fingerroot polysaccharides Download PDFInfo
- Publication number
- KR20150129344A KR20150129344A KR1020140056099A KR20140056099A KR20150129344A KR 20150129344 A KR20150129344 A KR 20150129344A KR 1020140056099 A KR1020140056099 A KR 1020140056099A KR 20140056099 A KR20140056099 A KR 20140056099A KR 20150129344 A KR20150129344 A KR 20150129344A
- Authority
- KR
- South Korea
- Prior art keywords
- finger root
- polysaccharide
- polysaccharides
- obesity
- root polysaccharide
- Prior art date
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 137
- 150000004676 glycans Chemical class 0.000 title claims abstract description 136
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 136
- 244000060701 Kaempferia pandurata Species 0.000 title claims abstract description 114
- 235000016390 Uvaria chamae Nutrition 0.000 title claims abstract description 113
- 230000003178 anti-diabetic effect Effects 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 239000003472 antidiabetic agent Substances 0.000 title claims abstract description 9
- 230000003579 anti-obesity Effects 0.000 claims abstract description 29
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 22
- 229940088598 enzyme Drugs 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 9
- 238000001125 extrusion Methods 0.000 claims description 9
- 238000000108 ultra-filtration Methods 0.000 claims description 9
- 230000003301 hydrolyzing effect Effects 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 108010059892 Cellulase Proteins 0.000 claims description 6
- 108010059820 Polygalacturonase Proteins 0.000 claims description 5
- 229940106157 cellulase Drugs 0.000 claims description 5
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 4
- 108010002430 hemicellulase Proteins 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 230000007928 solubilization Effects 0.000 claims description 4
- 238000005063 solubilization Methods 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 229940059442 hemicellulase Drugs 0.000 claims description 3
- 101710130006 Beta-glucanase Proteins 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 24
- 210000004369 blood Anatomy 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 14
- 239000008103 glucose Substances 0.000 abstract description 14
- 102000004877 Insulin Human genes 0.000 abstract description 12
- 108090001061 Insulin Proteins 0.000 abstract description 12
- 229940125396 insulin Drugs 0.000 abstract description 12
- 210000000577 adipose tissue Anatomy 0.000 abstract description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000010171 animal model Methods 0.000 description 11
- 230000009467 reduction Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 201000010063 epididymitis Diseases 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 235000009200 high fat diet Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000004382 Amylase Substances 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 5
- 102100022624 Glucoamylase Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 108010065511 Amylases Proteins 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108010075550 termamyl Proteins 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- FARHYDJOXLCMRP-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]pyrazol-3-yl]oxyacetic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(N1CC2=C(CC1)NN=N2)=O)OCC(=O)O FARHYDJOXLCMRP-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100205088 Caenorhabditis elegans iars-1 gene Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 238000010159 Duncan test Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 101150030450 IRS1 gene Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 235000013412 Kaempferia pandurata Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- LYDZCXVWCFJAKQ-ZFGGDYGUSA-N Panduratin A Chemical compound OC1=CC(OC)=CC(O)=C1C(=O)[C@H]1[C@H](C=2C=CC=CC=2)CC=C(C)[C@H]1CC=C(C)C LYDZCXVWCFJAKQ-ZFGGDYGUSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- LYDZCXVWCFJAKQ-UHFFFAOYSA-N nicolaioidesin A Natural products OC1=CC(OC)=CC(O)=C1C(=O)C1C(C=2C=CC=CC=2)CC=C(C)C1CC=C(C)C LYDZCXVWCFJAKQ-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000899 pressurised-fluid extraction Methods 0.000 description 1
- 238000009910 pressurized microwave-assisted extraction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
본 발명은 핑거루트(fingerroot)로부터 분리된 다당류, 그의 제조방법 및 분리된 다당류의 용도에 관한 것이다. 보다 구체적으로 본 발명은 생강과 식물의 일종인 핑거루트로부터 분리된 핑거루트 다당류 복합체(fingerroot polysaccharide complex), 알카리 가용성 핑거루트 다당류(alkaline soluble fingerroot polysaccharides), 산 가용성 핑거루트 다당류(acid soluble fingerroot polysaccharides), 효소 가용성 핑거루트 다당류(enzyme soluble fingerroot polysaccharides), 압출성형 가용성 핑거루트 다당류(extrusion soluble fingerroot polysaccharides)를 함유하는 것을 특징으로 하는 항비만 및 항당뇨 조성물에 관한 것이다.
The present invention relates to polysaccharides isolated from fingerroots, methods for their preparation and uses of isolated polysaccharides. More particularly, the present invention relates to a fingerroot polysaccharide complex, an alkaline soluble fingerroot polysaccharide, an acid soluble fingerroot polysaccharide, and the like, which are separated from a finger root, An enzyme soluble fingerroot polysaccharides, and extrusion soluble fingerroot polysaccharides. The present invention also relates to an anti-obesity and anti-diabetic composition.
비만은 에너지 축적량과 소모량의 불균형으로 지방조직의 이상적 증가에 따라 발생하는 질환이다. 비만은 세계 각국에서 심각한 보건문제로 인식되고 있으며 우리나라 역시 고도의 산업성장과 식생활 패턴의 서구화 및 신체 활동량 부족 등 다양한 원인에 의해 비만 유병률이 급속히 증가하는 추세이다. 비만은 그 자체가 갖는 문제점뿐만 아니라 고인슐린혈증, 동맥경화증, 순환기계 질환, 암, 당뇨병 등과 같은 많은 질병의 원인으로도 작용할 수 있어 그 심각성이 더욱 고조되고 있는 실정이다(Nature 404(6778): 635-43, 2000, Obes. Rev. 12(1): 1-13, 2011).Obesity is a disease caused by an ideal increase in adipose tissue due to an imbalance of energy accumulation and consumption. Obesity is recognized as a serious health problem in many countries around the world. In Korea, too, the prevalence of obesity is rapidly increasing due to various reasons such as high industrial growth, westernization of diet patterns and lack of physical activity. Obesity is a cause of many diseases such as hyperinsulinemia, arteriosclerosis, circulatory system diseases, cancer, diabetes and the like, as well as the problems themselves. (Nature 404 (6778): 635-43, 2000, Obes. Rev. 12 (1): 1-13, 2011).
당뇨병은 크게 제 1 형과 제 2 형 당뇨병으로 나눌 수 있는데 제 1 형 당뇨병은 유전적 감수성 및 바이러스 감염으로 인해 췌장에 면역학적 반응이 유발되고, -세포가 선택적으로 파괴되어 발생하는 자가면역질환이다. 제 2 형 당뇨병은 인슐린 저항성이 선행하는 형으로 주요 병인으로는 비만, 인슐린 수용체의 감소, tyrosine kinase 활성도 감소, 근육조직과 지방조직의 muscle/adipose tissue type transportor의 감소, insulin receptor substrate-1(IRS-1)의 세포 내 결핍 등 복잡한 원인에 의해 발병하는 것으로 보고되고 있다. 제 2 형 당뇨병은 주로 성인에서 발병하는데 전체 당뇨병 중 90%를 차지하고 있다(Drugs, 65: 433-445, 2005).Diabetes mellitus can be classified into Type 1 and
다당류(Polysaccharides)는 당의 중합체로 구성된 물질로서 식품에서는 안정제, 증점제, 유화제 등의 용도로 사용된다. 영양학적으로는 비전문성 다당류(non-starch polysacchrides)의 경우 인체내의 소화효소에 분해되지 않는 식이섬유(dietary fiber)로서 작용하여 배변활동을 원활하게 하거나 혈중 콜레스테롤를 감소시키는 생리작용을 제공한다. 또한, 일부 약리작용이 있는 다당류의 경우 면역활성이나 항암활성을 나타내기도 한다. Polysaccharides are substances composed of sugar polymers, and they are used in foods as stabilizers, thickeners, emulsifiers and the like. Nutritionally, non-starch polysaccharides act as dietary fibers that are not degraded by the digestive enzymes in the body, thereby providing a physiological effect that smoothes bowel movements or reduces blood cholesterol. In addition, polysaccharides having some pharmacological actions may exhibit immunological activity or anticancer activity.
핑거루트(Fingerroot)는 생강과의 일종인 보에센버지아 판두라타(Boesenbergia pandurata (Roxb.) Schltr.)의 근경(rhizone)과 뿌리(roots)에서 얻어지는 부위로서 동남아시아 열대지역에서 향신료서 사용되고 있으며, 항균 및 항염작용이 강하여 전통 의약품으로도 널리 사용되어 왔다(End-Chong et al., Evidence-based Complementary and Alternative Medicine, Volume 2012, Article ID 473637). 또한, 핑거루트의 에탄올 추출물 및 이로부터 분리된 판두라틴 에이 성분은 저분자 화합물(small molecules)로서 항비만 및 항당뇨 효과가 있는 것으로 보고된 바 있다(Kim et al., Diabetes, Obesity and Metabolism, 13:584-593, 2011; Kim et al., International Journal of Molecular Science, 13:994-1005, 2012). 그러나 지금까지 핑거루트 다당류 성분의 구체적인 기능성에 대하여는 밝혀진 바 없다.
Fingerroot is obtained from rhizone and roots of ginger (Boesenbergia pandurata (Roxb.) Schltr.) And is used as a spice in tropical regions of Southeast Asia. (End-Chong et al., Evidence-based Complementary and Alternative Medicine, Volume 2012, Article ID 473637). In addition, the ethanol extract of Finger root and the Panduratin A component isolated therefrom have been reported to have anti-obesity and antidiabetic effects as small molecules (Kim et al., Diabetes, Obesity and Metabolism, 13 : 584-593, 2011; Kim et al., International Journal of Molecular Science, 13: 994-1005, 2012). However, the specific functionality of the finger root polysaccharide component has not yet been elucidated.
따라서 본 발명의 목적은 핑거루트 다당류를 유효성분으로 포함하는 항비만 및 항당뇨 식품 조성물을 제공하는 것이다. It is therefore an object of the present invention to provide an anti-obesity and antidiabetic food composition comprising a finger root polysaccharide as an active ingredient.
본 발명의 다른 목적은 핑거루트 다당류를 유효성분으로 포함하는 항비만 및 항당뇨 약학적 조성물을 제공하는 것이다.
Another object of the present invention is to provide an anti-obesity and antidiabetic pharmaceutical composition comprising a finger root polysaccharide as an active ingredient.
본 발명의 상기 목적을 달성하기 위하여 핑거루트에 유기용매를 가하여 용매 가용화 분획을 제거함으로써 핑거루트 다당류 복합체(fingerroot polysaccharide complex)를 제조하였다. 유기용매로는 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol), 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethylacetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane), 시클로헥산(cyclohexane), 석유에테르(petroleum ether) 등 단독으로 혹은 혼합하여 사용될 수 있으나, 이에 한정되는 것은 아니다. In order to achieve the above object of the present invention, a fingerroot polysaccharide complex was prepared by adding an organic solvent to finger roots and removing the solvent-soluble fraction. Examples of the organic solvent include methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl But are not limited to, ethylacetate, methylene chloride, hexane, cyclohexane, petroleum ether, etc., alone or in combination.
또한, 핑거루트의 다당류의 저분자 물질을 제거하기 위하여 초임계유체 추출(supercritical fluid extraction), 초음파 추출(ultrasonification extraction), 초고압추출(ultra-high pressure extraction), 아임계수 추출(subcritical water extraction), 고압용매 추출 (pressurized liquid extraction) 마이크로파 보조 추출(microwave-assisted extraction) 등의 기계적 추출방법을 단독으로 혹은 상기 용매 추출법과 병행하여 사용할 수 있다. In addition, supercritical fluid extraction, ultrasonification extraction, ultra-high pressure extraction, subcritical water extraction, high pressure Mechanical extraction methods such as pressurized liquid extraction and microwave-assisted extraction may be used alone or in combination with the above solvent extraction method.
이 때, 상기 용매 추출법이나 기계적 추출법으로 저분자 물질을 제거한 후 얻어진 핑거루트 다당류 복합체에 포함되어 있는 전분이나 단백질은 전분 가수분해효소(-amylase, glucoamylase 등)나 단백질 가수분해효소(proteases)를 처리함으로써 다당류 복합체의 순도를 향상시킬 수 있다. At this time, the starch or protein contained in the finger root polysaccharide complex obtained by removing the low molecular substance by the solvent extraction method or the mechanical extraction method is treated with starch hydrolyzing enzyme (such as -amylase, glucoamylase, etc.) or protease The purity of the polysaccharide complex can be improved.
또한, 본 발명의 상기 목적을 달성하기 위하여 상기 제조한 핑거루트 다당류 복합체에 알카리 용액을 가하여 알카리 가용화 핑거루트 다당류를 제조하였다. 이 때 알카리 용액은 0.01~10.0N NaOH 농도로, 보다 바람직하게는 0.1~1.0N NaOH 농도로 처리할 수 있다.In order to achieve the above object of the present invention, an alkaline solution was added to the above-prepared finger root polysaccharide complex to prepare an alkali-soluble finger root polysaccharide. In this case, the alkali solution can be treated with a concentration of 0.01 to 10.0 N NaOH, more preferably with a concentration of 0.1 to 1.0 N NaOH.
또한, 본 발명의 상기 목적을 달성하기 위하여 상기 제조한 핑거루트 다당류 복합체에 산 용액을 가하여 산 가용화 핑거루트 다당류를 제조하였다. 이 때 산 용액은 0.01~10.0N HCl 농도로, 보다 바람직하게는 0.1~1.0N HCl 농도로 처리할 수 있다.In order to achieve the above object of the present invention, an acid solution was added to the above-prepared finger root polysaccharide complex to prepare an acid-solubilized finger root polysaccharide. At this time, the acid solution can be treated with a HCl concentration of 0.01 to 10.0 N, more preferably 0.1 to 1.0 N HCl.
또한, 본 발명의 상기 목적을 달성하기 위하여 상기 제조한 핑거루트 다당류 복합체에 효소 용액을 가하여 효소 가용화 핑거루트 다당류를 제조하였다. 이 때 효소로는 셀룰라제(cellulase), 펙티나제(pectinases), 헤미셀룰라제(hemicellulases), 베타클루카나제(beta-glucanse) 등의 식물 세포벽 가수분해 효소(plant cell wall hydrolyzing enzymes)를 단독으로 혹은 2종 이상 복합하여 적용할 수 있다. In order to achieve the above object of the present invention, an enzyme solution was added to the finger root polysaccharide complex prepared above to prepare an enzyme-solubilized finger root polysaccharide. The enzymes include plant cell wall hydrolyzing enzymes such as cellulase, pectinases, hemicellulases, and beta-glucanse. Or a combination of two or more.
본 발명에서 사용한 셀룰라제로서 셀루클라스트(Celluclast, Novo Nordisk, Denmark)를, 헤미셀룰라제로서 비스코자임(Viscozyme, Novo Nordisk, Denmark)을, 펙티나제로서 펙티넥스(Pectinex, Novo Nordisk, Denmark)를, 베타클루카나제로서 울트라플로(Ultraflo, Novo Nordisk, Denmark)를 사용하였다. (Celluclast, Novo Nordisk, Denmark) as a cellulase used in the present invention, Viscozyme (Novo Nordisk, Denmark) as a hemicellulase, Pectinex (Novo Nordisk, Denmark) as a pectinase, (Ultraflo, Novo Nordisk, Denmark) was used as a beta-glucanase.
상기 핑거루트 다당류 복합체를 증류수에 10%(w/v) 첨가한 후 핑거루트 다당류 복합체에 대한 중량비로 상업용 가수분해 효소인 셀룰라제, 헤미셀룰라제, 펙티나제, 베타클루카나제를 1:0.01을 가한 후 효소의 반응조건에 따라 pH 4~6, 온도 40~60, 100 rpm에서 6시간 교반한다. 상기 시료를 100에서 10분간 가열하여 효소를 불활성화 한 다음 6,500 rpm에서 15분간 원심분리 하여 다당류가 함유된 상등액을 획득하였다. After adding 10% (w / v) of the finger root polysaccharide complex to the distilled water, the commercial hydrolytic enzymes cellulase, hemicellulase, pectinase and betaclucanase were dissolved in a weight ratio of 1: 0.01 Followed by stirring at
또한, 본 발명의 상기 목적을 달성하기 위하여 상기 제조한 핑거루트 다당류 복합체를 압출성형(extrusion)하여 기계적 힘에 의하여 가용화 핑거루트 다당류를 제조할 수 있다. 압출성형은 핑거루트 다당류 복합체를 L/D비(length:diameter ratio) 2040의 이축 압출성형기에 투입한 후 스크류 속도 150400rpm, 시료 투입속도 2060kg/hr, 수분함량 1540%의 조건에서 압출성형을 실시할 수 있다.In order to achieve the above object of the present invention, the finger root polysaccharide complex may be extruded to produce a solubilized finger root polysaccharide by mechanical force. The extrusion molding was performed by extruding a finger root polysaccharide complex into a biaxial extrusion molding machine having a length: diameter ratio of 2040, and then extruding at a screw speed of 150400 rpm, a sample feed rate of 2060 kg / hr, and a moisture content of 1540% .
본 발명의 알카리 가용성 핑거루트 다당류, 산 가용성 핑거루트 다당류, 효소 가용성 핑거루트 다당류 및 압출성형 가용성 핑거루트 다당류 제조방법은 다당류가 함유된 용액에 전분 가수분해효소를 가하여 전분을 제거하는 단계를 포함한다. 바람직하게, 전분 가수분해효소로는 -amylase, glucoamylase 등이 사용될 수 있다. 또한 단백질 성분을 제거하기 위하여 단백질 가수분해효소를 처리할 수 있다.The method for preparing an alkali-soluble finger root polysaccharide, an acid-soluble finger root polysaccharide, an enzyme-soluble finger root polysaccharide and an extrusion-formable finger root polysaccharide according to the present invention includes a step of adding starch hydrolyzing enzyme to a solution containing polysaccharides to remove starch . Preferably, amylase, glucoamylase and the like may be used as the starch hydrolyzing enzyme. Protein hydrolysates can also be treated to remove protein components.
본 발명의 알카리 가용성 핑거루트 다당류, 산 가용성 핑거루트 다당류, 효소 가용성 핑거루트 다당류 제조방법은 다당류를 분획 정제하는 단계를 포함한다. 다당류 분획은 투석(dialysis), 한외여과(ultrafiltration) 등의 분자량 분획 시스템을 이용하여 저분자량의 성분을 제거함으로써 다당류가 정제될 수 있다. 투석, 한외여과 등에 있어 분자량 cut-off 기준이 500 내지 10,000, 바람직하게는, 500 내지 5,000, 더욱 바람직하게는 1,000 내지 5,000인 멤브레인(membrane)이 사용될 수 있다.The method for preparing an alkali-soluble finger root polysaccharide, an acid-soluble finger root polysaccharide, and an enzyme-soluble finger root polysaccharide of the present invention includes fractionating a polysaccharide. The polysaccharide fraction can be purified by removing a low molecular weight component using a molecular weight fractionation system such as dialysis or ultrafiltration. A membrane having a molecular weight cut-off criterion of 500 to 10,000, preferably 500 to 5,000, more preferably 1,000 to 5,000 may be used for dialysis and ultrafiltration.
본 발명의 다른 목적을 달성하기 위하여 상기 제조한 핑거루트 다당류 복합체, 알카리 가용성 다당류, 산가용성 다당류, 효소 가용성 다당류, 압출성형 가용성 다당류가 체중 및 체지방을 유의적으로 감소시켜 항비만 활성을 제공하는 것을 동물실험을 통하여 확인하였다. In order to accomplish another object of the present invention, the finger root polysaccharide complex, the alkali-soluble polysaccharide, the acid-soluble polysaccharide, the enzyme-soluble polysaccharide, and the extruded soluble polysaccharide produced by the present invention significantly reduce body weight and body fat to provide anti- It was confirmed through animal experiments.
본 발명의 다른 목적을 달성하기 위하여 상기 제조한 핑거루트 다당류 복합체, 알카리 가용성 다당류, 산가용성 다당류, 효소 가용성 다당류, 압출성형 가용성 다당류가 공복 혈당과 공복 인슐린을 유의적으로 감소시켜 항당뇨 활성을 제공하는 것을 동물실험을 통하여 확인하였다. In order to achieve the other object of the present invention, the finger root polysaccharide complex, the alkali-soluble polysaccharide, the acid-soluble polysaccharide, the enzyme-soluble polysaccharide and the extruded soluble polysaccharide produced the antidiabetic activity by significantly reducing fasting glucose and fasting insulin Was confirmed by animal experiments.
본 발명은 상기 제조방법에 의해 얻어진 핑거루트 다당류를 제공하며, 또한 이러한 다당류가 유효성분으로 포함된 기능성 식품 및 약학 조성물을 제공한다. The present invention provides a finger root polysaccharide obtained by the above production method, and also provides a functional food and a pharmaceutical composition containing such a polysaccharide as an active ingredient.
본 발명의 제조방법에 따라 얻어진 핑거루트 다당류를 포함하는 조성물은 본 발명이 속한 분야에서 통상의 지식을 가진 자에게 잘 알려진 방법에 따라 의약품 및 기능성 식품의 형태로 제조될 수 있다. 이러한 의약품 및 기능성 식품은 약제학적으로 허용되는 부형제 또는 첨가제를 포함할 수 있다. 본 발명의 다당류를 포함하는 조성물은 단독으로 혹은 어떤 편리한 운반체, 부형제 등과 함께 혼합하여 투여될 수 있고, 그러한 투여 제형은 단회투여 또는 반복투여 제형일 수 있다. Compositions comprising the finger root polysaccharides obtained according to the process of the present invention may be prepared in the form of pharmaceuticals and functional foods according to methods well known to those skilled in the art. Such medicaments and functional foods may include pharmaceutically acceptable excipients or additives. Compositions comprising the polysaccharides of the present invention may be administered alone or in admixture with any convenient vehicle, excipient, or the like, and such dosage forms may be single or multiple dose formulations.
본 발명의 조성물을 포함하는 의약품 또는 기능성 식품은 고형 제제 또는 액상 제제일 수 있다. 고형 제제는 산제, 과립제, 정제, 캅셀제, 좌제 등이 있으나, 이에 한정되는 것은 아니다. 고형 제제에는 부형제, 착향제, 결합제, 방부제, 붕해제, 활택제, 충진제 등이 포함될 수 있으나 이에 한정되는 것은 아니다. 액상 제제로는 물, 프로필렌 글리콜 용액 같은 용액제, 현탁액제, 유제 등이 있으나, 이에 한정되는 것은 아니며, 적당한 착색제, 착향제, 안정화제, 점성화제 등을 첨가하여 제조할 수 있다.The pharmaceutical or functional food containing the composition of the present invention may be a solid preparation or a liquid preparation. Solid preparations include, but are not limited to, powders, granules, tablets, capsules, suppositories, and the like. Solid form preparations may include, but are not limited to, excipients, flavoring agents, binders, preservatives, disintegrants, lubricants, fillers, and the like. Examples of the liquid preparation include water, a solution such as a solution of propylene glycol, a suspension, an emulsion, and the like, but not limited thereto, and it can be prepared by adding a suitable coloring agent, a flavoring agent, a stabilizer, a tackifying agent and the like.
예를 들어, 산제는 본 발명의 다당류와 유당, 전분, 미결정셀룰로오스 등의 약제학적으로 허용되는 적당한 부형제를 단순 혼합함으로써 제조될 수 있다. 과립제는 본 발명의 다당류; 약제학적으로 허용되는 적당한 부형제; 및 폴리비닐피롤리돈, 히드록시프로필셀룰로오스 등의 약제학적으로 허용되는 적당한 결합제를 혼합한 후, 물, 에탄올, 이소프로판올 등의 용매를 이용한 습식과립법 또는 압축력을 이용한 건식과립법을 이용하여 제조될 수 있다. 또한 정제는 상기 과립제를 마그네슘 스테아레이트 등의 약제학적으로 허용되는 적당한 활택제화 혼합한 후, 타정기를 이용하여 타정함으로써 제조될 수 있다.For example, powders can be prepared by simple mixing of the polysaccharides of the present invention with suitable pharmaceutically acceptable excipients such as lactose, starch, microcrystalline cellulose and the like. The granule is a polysaccharide of the present invention; Suitable excipients which are pharmaceutically acceptable; And a suitable pharmaceutically acceptable binder such as polyvinylpyrrolidone and hydroxypropylcellulose, followed by wet granulation using a solvent such as water, ethanol or isopropanol or dry granulation using a compressive force . Further, the tablet may be prepared by mixing the above granule with a suitable pharmaceutically acceptable salt such as magnesium stearate and then tableting it using a tablet machine.
본 발명의 조성물은 치료해야할 질환 및 개체의 상태에 따라 경구제, 직장투여제, 설하제 등으로 투여될 수 있으나, 이에 한정되는 것은 아니다. 투여경로에 따라 통상적으로 사용되고 비독성인, 약제학적으로 허용되는 운반체, 첨가제, 비히클(vehicle)을 포함하는 적당한 투여 유닛 제형으로 제제화될 수 있다. The composition of the present invention may be administered orally, rectally, or sublingually, depending on the disease to be treated and the condition of the individual, but is not limited thereto. May be formulated into suitable dosage unit formulations, including those conventionally used and non-toxic, pharmaceutically acceptable carriers, additives, vehicles according to the route of administration.
본 발명의 다당류는 매일 약 0.2 내지 약 200 mg/kg이 투여될 수 있으며, 약 2 내지 약 50 mg/kg의 1일 투여 용량이 바람직하고, 약 5 내지 약 30 mg/kg의 1일 투여 용량이 더욱 바람직하다. 그러나 상기 투여량은 환자의 상태(연령, 성별, 체중 등), 치료하고 있는 상태의 심각성, 사용된 유효 성분, 식이 등에 따라 다양할 수 있다. 필요에 따라 편리성을 위하여 1일 총 투여량이 나누어지고 하루 동안 여러 번 나누어 투여될 수 있다.The polysaccharides of the present invention may be administered in a daily dose of about 0.2 to about 200 mg / kg, with a daily dose of about 2 to about 50 mg / kg being preferred, and a daily dosage of about 5 to about 30 mg / Is more preferable. However, the dosage may vary depending on the condition (age, sex, weight, etc.) of the patient, the severity of the condition being treated, the active ingredient used, the diet and the like. For convenience, the total daily dose may be divided as needed and divided into several doses throughout the day.
본 발명은 본 발명에 따른 다당류를 유효성분으로 투여하는 것을 특징으로 하는 항비만 및 항당뇨 치료 방법을 제공한다.The present invention provides an anti-obesity and anti-diabetic therapeutic method, wherein the polysaccharide according to the present invention is administered as an active ingredient.
본 발명의 다당류를 래트에 경구 투여하여 독성 실험을 수행한 결과, 경구 독성시험에 의한 50% 치사량(LD50)은 2,000 mg/kg 이상인 것으로 나타나, 본 발명에 따른 다당류가 매우 안전하다는 것을 확인할 수 있었다.
The polysaccharide of the present invention was orally administered to rats and the toxicity test was conducted. As a result, the 50% lethal dose (LD 50 ) by oral toxicity test was 2,000 mg / kg or more and it was confirmed that the polysaccharide according to the present invention is very safe there was.
이상 살펴본 바와 같이, 본 발명의 핑거루트 다당류는 체중 및 체지방을 유의적으로 감소시켜 항비만 효과를 제공하였으며, 공복 혈당과 공복 인슐린을 유의적으로 감소시켜 항당뇨 효과를 제공하였다.
As described above, the finger root polysaccharide of the present invention significantly reduced body weight and body fat to provide an anti-obesity effect, and significantly reduced fasting glucose and fasting insulin, thereby providing an anti-diabetic effect.
도 1은 본 발명에 따른 핑거루트 다당류 복합체(FPC)의 섭취에 따른 마우스 체중의 감소를 나타낸 것이다.
도 2는 본 발명에 따른 핑거루트 다당류 복합체(FPC)의 섭취에 따른 마우스 부고환지방의 감소를 나타낸 것이다.
도 3은 본 발명에 따른 핑거루트 다당류 복합체(FPC)의 섭취에 따른 마우스 공복 혈당의 감소를 나타낸 것이다.
도 4는 본 발명에 따른 핑거루트 다당류 복합체(FPC)의 섭취에 따른 마우스 공복 인슐린 농도의 감소를 나타낸 것이다. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the decrease in mouse body weight following ingestion of Finger root polysaccharide complex (FPC) according to the present invention.
Figure 2 shows the reduction of mouse epididymal fat following ingestion of the Finger root polysaccharide complex (FPC) according to the present invention.
Figure 3 shows the decrease in fasting blood glucose levels of the mice according to the ingestion of Finger root polysaccharide complex (FPC) according to the present invention.
Figure 4 shows the decrease in fasting insulin levels of mice according to the ingestion of Finger root polysaccharide complex (FPC) according to the present invention.
이하, 본 발명을 보다 구체적으로 설명하기 위하여 하기 실시예 등을 들어 설명한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며 본 발명의 범위가 아래에서 상술하는 실시예 들에 한정되는 것으로 해석돼서는 안 된다. 본 발명의 실시예들은 본 발명의 구체적 이해를 돕기 위해 예시적으로 제공되는 것이다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the embodiments described below. The embodiments of the present invention are provided by way of example to facilitate a specific understanding of the present invention.
이하의 모든 시험 결과에 있어, 활성 분석은 3회 이상 반복 수행하였으며, 그 결과는 평균표준편차로 표시하였다. 통계분석은 Duncan test(SPSS 12.0)를 이용하여 수행하였으며, *p 값은 0.05, **p 값은 0.01 이하인 경우에 통계적으로 유의한 것으로 판정하였다.
In all of the following test results, the activity assay was repeated three or more times and the results were expressed as mean standard deviation. Statistical analysis was performed using the Duncan test (SPSS 12.0), with * p values of 0.05 and ** p values of 0.01 or less statistically significant.
<실시예 1> 핑거루트 다당류 복합체의 제조Example 1: Preparation of finger root polysaccharide complex
건조한 핑거루트 분말 100 g에 95% 에탄올 1,000 ml을 첨가하여 80에서 4시간 동안 추출한 후 원심분리하여 침전물을 얻었다. 이 침전물을 에탄올, 헥산 등의 유기용매를 이용하여 완전히 세척한 후 용매를 제거함으로써 핑거루트 다당류 복합체(fingerroot polysaccharide complex; FPC) 83.4g를 제조하였다.
1,000 g of 95% ethanol was added to 100 g of dried finger root powder, and the mixture was extracted at 80 for 4 hours, followed by centrifugation to obtain a precipitate. This precipitate was thoroughly washed with an organic solvent such as ethanol and hexane and then the solvent was removed to prepare 83.4 g of a fingerroot polysaccharide complex (FPC).
<실험예 1> 동물모델에서 핑거루트 다당류 복합체의 항비만 효과Experimental Example 1 Anti-obesity effect of finger root polysaccharide complex in animal model
5주령의 수컷 C57BL/6J 마우스를 각각 5마리씩 대조군(HFD 단독 투여군)과 시험군(핑거루트 다당류 투여군)으로 임의 배치한 후, 1주일간 실험 동물실 환경에 적응시켰다. 본 발명에서는 고지방 식이(high fat diet; HFD) (Product # D12451, Research Diet Inc., New Brunswick, NJ, USA; 40% kcal from fat)를 사용하였으며, 실시예 1의 핑거루트 다당류 복합체가 5중량%가 되도록 HFD 사료에 골고루 혼합하였다. 대조군과 시험군 모두 7주 동안 HFD를 급여시킨 후, 다음 8주 동안 대조군은 HFD 단독으로, 시험군은 핑거루트 다당류 복합체 함유 HFD를 각각 급여하였다. 이 때, 대조군과 시험군 간 총 시료섭취 양에는 유의적인 차이가 없었다. 5-week-old male C57BL / 6J mice were each randomly assigned to a control group (HFD monotherapy group) and a test group (finger root polysaccharide group) by 5 mice, respectively, and then adapted to the laboratory animal room environment for 1 week. In the present invention, a high fat diet (HFD) (Product # D12451, Research Diet Inc., New Brunswick, NJ, USA; 40% kcal from fat) was used and the finger root polysaccharide complex of Example 1 contained 5 wt% % Of HFD feed. In both the control and the test groups, HFD was fed for 7 weeks, followed by HFD alone for the control group and HFD containing the finger root polysaccharide complex for the next 8 weeks. At this time, there was no significant difference in the total sample intake between the control and test groups.
8주간의 시료 급여 후 체중을 측정한 결과 도 1에 나타낸 바와 같이 실시예 1의 핑거루트 다당류 복합체를 급여한 시험군의 체중이 대조군에 비하여 16.1% (p<0.05) 감소하였다. 또한, 8주간의 시료 급여 후 12시간 절식시키고 나서 마우스를 희생하여 부고환 지방을 적출하여 무게를 특정한 결과 도 2에 나타낸 바와 같이 실시예 1의 핑거루트 다당류 복합체를 급여한 시험군의 부고환 지방의 무게가 대조군에 비하여 29.4% (p<0.01) 감소하였다. 이러한 결과는 본 발명의 핑거루트 다당류 복합체가 체중 및 체지방 감소 효과를 제공하는 것을 의미한다
As shown in FIG. 1, the body weight of the test group fed with the finger root polysaccharide complex of Example 1 was 16.1% (p <0.05) lower than that of the control group after 8 weeks of sample feeding. In addition, after 8-week sample feeding, mice were sacrificed for 12 hours, sacrificed epididymal fat was weighed and weight was determined. As a result, the weight of epididymal fat of the test group fed with the finger root polysaccharide complex of Example 1 Was decreased by 29.4% (p <0.01) compared with the control group. These results indicate that the finger root polysaccharide complex of the present invention provides body weight and body fat reduction effects
<< 실험예Experimental Example 2> 동물모델에서 2> In the animal model 핑거루트Finger root 다당류 복합체의 Polysaccharide complex 항당뇨Anti-diabetic 효과 effect
상기 실험예 1의 8주간 시료를 급여한 후 12시간 절식시킨 마우스의 꼬리정맥으로부터 채혈된 혈청을 이용하여 공복 혈당 및 인슐린을 측정하였다. 공복혈당은 혈당측정기(Handok, Seoul, Korea)를 이용하여 측정하였으며, 혈청 인슐린은 효소면역측정법(Enzyme-linked immunosorbent assays, ELISA)을 이용하여 측정하였다. 실험 결과, 도 3과 4에서 보듯이 대조군(HFD)에 비해서 실시예 1의 핑거루트 다당류 복합체를 섭취시킨 시험군의 공복 혈당과 공복 인슐린이 대조군에 비하여 각각 26.3%(p<0.05)와 33.9%(p<0.01)로 유의하게 감소하였다. 이러한 결과는 본 발명의 핑거루트 다당류 복합체가 항당뇨 효과를 제공하는 것을 의미한다.
Fasting blood glucose and insulin were measured using the serum collected from the tail vein of the mice that were fasted for 12 hours after the 8-week sample of Experimental Example 1 was fed. Fasting blood glucose was measured using a blood glucose meter (Handok, Seoul, Korea) and serum insulin was measured using enzyme-linked immunosorbent assays (ELISA). As shown in FIGS. 3 and 4, fasting blood glucose and fasting insulin in the test group of the finger root polysaccharide complex of Example 1 were 26.3% (p <0.05) and 33.9%, respectively, as compared with the control (HFD) (p <0.01), respectively. These results indicate that the finger root polysaccharide complex of the present invention provides an antidiabetic effect.
<< 실시예Example 2> 2> 알카리Alkaline 가용성 Availability 핑거루트Finger root 다당류의 분리 Separation of polysaccharides
상기 실시예 1에서 제조된 핑거루트 다당류 복합체 15g에 추출 용매로서 750 ml의 0.1 N NaOH를 가한 후 97에서 2시간 동안 2회 추출하였다. 상기에서 얻어진 0.1 N NaOH 추출물에 포함되어 있는 전분을 가수분해하기 위해 효소 최적 조건에서 -아밀라제(-amylase; Termamyl 120L, NOVO Nordisk A/S, Denmark)와 글루코아밀라제(glucoamylase; AMG 300L, NOVO Nordisk A/S, Denmark)를 처리한 후 중화하였다. 상기 여액에 4배 부피의 이소프로필 알코올(isopropyl alcohol)을 가하고 4에서 24시간 방치하여 다당류를 침전시킨 후 6,500 rpm에서 15분간 원심분리하여 상등액과 분리하였다. 분리된 침전물을 건조한 후 1% 용액이 되도록 증류수에 녹여 분자량(molecular weight) cut off(MWCO)가 1000인 막(membrane)을 이용하여 한외여과(thin channel ultrafiltration system, Amicon TCF-10; Amicon Co., U.S.A.)하였다. 한외 여과 후 분자량 1000이상의 용액을 모아 동결건조함으로써 알카리 가용성 핑거루트 다당류(alkali soluble fingerroot polysaccharides)를 얻었다. 이때 수율은 8.4%였다.
750 ml of 0.1 N NaOH was added as an extraction solvent to 15 g of the finger root polysaccharide complex prepared in Example 1, and then extracted twice at 97 for 2 hours. Amylase (Termamyl 120L, NOVO Nordisk A / S, Denmark) and glucoamylase (AMG 300L, NOVO Nordisk A) were hydrolyzed at the optimum conditions of enzyme to hydrolyze the starch contained in the 0.1 N NaOH extract obtained above. / S, Denmark) and neutralized. Isopropyl alcohol (4-fold volume) was added to the filtrate, and the mixture was allowed to stand for 4 to 24 hours to precipitate the polysaccharide. Then, the filtrate was centrifuged at 6,500 rpm for 15 minutes to separate the supernatant. The separated precipitate was dried and dissolved in distilled water so that it became a 1% solution. Using a membrane having a molecular weight cut-off (MWCO) of 1000, a thin channel ultrafiltration system (Amicon TCF-10; , USA). After the ultrafiltration, a solution having a molecular weight of 1000 or more was collected and lyophilized to obtain alkali soluble fingerroot polysaccharides. The yield was 8.4%.
<< 실험예Experimental Example 3> 동물모델에서 3> In the animal model 알카리Alkaline 가용성 Availability 핑거루트Finger root 다당류의 Polysaccharide 항비만Anti-obesity 효과 effect
상기 실시예 2에서 제조된 알카리 가용성 핑거루트 다당류의 항당뇨 효과를 상기 실험예 1과 동일한 방법으로 실험한 결과 시험군의 체중 및 부고환 지방의 무게가 대조군에 비하여 각각 17.8% (p<0.01) 및 14.9% (p<0.05) 감소하였다. 이러한 결과는 본 발명의 알카리 가용성 핑거루트 다당류가 체중 및 체지방 감소 효과를 제공하는 것을 의미한다.
The anti-diabetic effect of the alkali-soluble finger root polysaccharide prepared in Example 2 was tested in the same manner as in Experimental Example 1, and the weight of the test group and epididymal fat weight were 17.8% (p < 0.01) 14.9% (p < 0.05). These results indicate that the alkali-soluble finger root polysaccharides of the present invention provide body weight and body fat reduction effects.
<< 실험예Experimental Example 4> 동물모델에서 4> In the animal model 알카리Alkaline 가용성 Availability 핑거루트Finger root 다당류의 Polysaccharide 항당뇨Anti-diabetic 효과 effect
상기 실시예 2에서 제조된 알카리 가용성 핑거루트 다당류의 항비만 효과를 상기 실험예 2과 동일한 방법으로 실험한 결과 시험군의 공복 혈당과 공복 인슐린이 대조군에 비하여 각각 14.2% (p<0.05)와 18.4% (p<0.01) 감소하였다. 이러한 결과는 본 발명의 알카리 가용성 핑거루트 다당류가 항당뇨 효과를 제공하는 것을 의미한다.
The anti-obesity effect of the alkali-soluble finger root polysaccharide prepared in Example 2 was tested in the same manner as in Experimental Example 2. As a result, fasting blood glucose and fasting insulin in the test group were 14.2% (p <0.05) and 18.4 % (p < 0.01). These results indicate that the alkali-soluble finger root polysaccharides of the present invention provide an antidiabetic effect.
<< 실시예Example 3-5> 추출조건별 3-5> By extraction condition 알카리Alkaline 가용화Solubilization 핑거루트Finger root 다당류의 항비만 및 The anti-obesity of polysaccharides and 항당뇨Anti-diabetic 효과 effect
상기 실시예 2와 동일한 조건으로 0.05N, 1.0N, 5N의 NaOH 용액을 이용하여 알카리 가용화 핑거루트 다당류를 제조한 후 실험예 1 및 실험예 2의 방법으로 각각 체중 감소율 및 공복혈당 감소율을 측정 결과 표 1에 나타낸 바와 같이 유의적으로 항비만 및 항당뇨 효과를 나타내었다.
The alkali-solubilized finger root polysaccharide was prepared by using 0.05N, 1.0N, and 5N NaOH solution under the same conditions as in Example 2, and the weight loss rate and fasting blood glucose reduction rate were measured by the methods of Experimental Example 1 and Experimental Example 2, respectively As shown in Table 1, anti-obesity and anti-diabetic effects were significantly exhibited.
감소율(%)weight
Decrease (%)
감소율(%)Fasting blood sugar
Decrease (%)
<< 실시예Example 6> 산 가용성 6> Acid availability 핑거루트Finger root 다당류의 분리 Separation of polysaccharides
상기 실시예 1에서 제조된 핑거루트 다당류 복합체 15g에 추출 용매로서 750 ml의 0.1 N HCl을 가한 후 97에서 2시간 동안 2회 추출하였다. 상기에서 얻어진 0.1 N HCl 추출물에 포함되어 있는 전분을 가수분해하기 위해 효소 최적 조건에서 -아밀라제(-amylase; Termamyl 120L, NOVO Nordisk A/S, Denmark)와 글루코아밀라제(glucoamylase; AMG 300L, NOVO Nordisk A/S, Denmark)를 처리한 후 중화하였다. 상기 여액에 4배 부피의 이소프로필 알코올(isopropyl alcohol)을 가하고 4에서 24시간 방치하여 다당류를 침전시킨 후 6,500 rpm에서 15분간 원심분리하여 상등액과 분리하였다. 분리된 침전물을 건조한 후 1% 용액이 되도록 증류수에 녹여 분자량(molecular weight) cut off(MWCO)가 1000인 막(membrane)을 이용하여 한외여과(thin channel ultrafiltration system, Amicon TCF-10; Amicon Co., U.S.A.)하였다. 한외 여과 후 분자량 1000이상의 용액을 모아 동결건조함으로써 산 가용성 핑거루트 다당류(acid soluble fingerroot polysaccharides)를 얻었다. 이때 수율은 8.2%였다.
750 ml of 0.1 N HCl was added as an extraction solvent to 15 g of the finger root polysaccharide complex prepared in Example 1 and extracted twice at 97 for 2 hours. Amylase (Termamyl 120L, NOVO Nordisk A / S, Denmark) and glucoamylase (AMG 300L, NOVO Nordisk A) were hydrolyzed at the optimum conditions of enzyme to hydrolyze the starch contained in the 0.1 N HCl extract obtained above. / S, Denmark) and neutralized. Isopropyl alcohol (4-fold volume) was added to the filtrate, and the mixture was allowed to stand for 4 to 24 hours to precipitate the polysaccharide. Then, the filtrate was centrifuged at 6,500 rpm for 15 minutes to separate the supernatant. The separated precipitate was dried and dissolved in distilled water so that it became a 1% solution. Using a membrane having a molecular weight cut-off (MWCO) of 1000, a thin channel ultrafiltration system (Amicon TCF-10; , USA). After ultrafiltration, a solution having a molecular weight of 1000 or more was collected and lyophilized to obtain acid soluble fingerroot polysaccharides. The yield was 8.2%.
<< 실험예Experimental Example 5> 동물모델에서 산 가용성 5> Acid availability in animal models 핑거루트Finger root 다당류의 Polysaccharide 항비만Anti-obesity 효과 effect
상기 실시예 6에서 제조된 산 가용성 핑거루트 다당류의 항비만 효과를 상기 실험예 1과 동일한 방법으로 실험한 결과 시험군의 체중 및 부고환 지방의 무게가 대조군에 비하여 각각 10.6% (p<0.05) 및 22.7% (p<0.01) 감소하였다. 이러한 결과는 본 발명의 산 가용성 핑거루트 다당류가 체중 및 체지방 감소 효과를 제공하는 것을 의미한다.
The anti-obesity effect of the acid-soluble finger root polysaccharide prepared in Example 6 was tested in the same manner as in Experimental Example 1. The weight and epididymal fat weight of the test group were 10.6% (p < 0.05) And decreased by 22.7% (p <0.01). These results indicate that the acid-soluble finger root polysaccharides of the present invention provide body weight and body fat reduction effects.
<< 실험예Experimental Example 6> 동물모델에서 산 가용성 6> Acid availability in animal models 핑거루트Finger root 다당류의 Polysaccharide 항당뇨Anti-diabetic 효과 effect
상기 실시예 6에서 제조된 산 가용성 핑거루트 다당류의 항당뇨 효과를 상기 실험예 2과 동일한 방법으로 실험한 결과 시험군의 공복 혈당과 공복 인슐린이 대조군에 비하여 각각 12.6% (p<0.05) 및 20.4% (p<0.01) 감소하였다. 이러한 결과는 본 발명의 산 가용성 핑거루트 다당류가 항당뇨 효과를 제공하는 것을 의미한다.
The anti-diabetic effect of the acid-soluble finger root polysaccharides prepared in Example 6 was tested in the same manner as in Experimental Example 2. As a result, fasting glucose and fasting insulin in the test group were 12.6% (p <0.05) and 20.4 % (p < 0.01). These results indicate that the acid-soluble finger root polysaccharides of the present invention provide an antidiabetic effect.
<< 실시예Example 7-9> 추출조건별 산 7-9> Mountain by extraction condition 가용화Solubilization 핑거루트Finger root 다당류의 Polysaccharide 항비만Anti-obesity 및 And 항당뇨Anti-diabetic 효과 effect
상기 실시예 2와 동일한 조건으로 0.05N, 1.0N, 5N의 HCl 용액을 이용하여 산 가용화 핑거루트 다당류를 제조한 후 실험예 1 및 실험예 2의 방법으로 각각 체중 감소율 및 공복혈당 감소율을 측정 결과 표 2에 나타낸 바와 같이 유의적으로 항비만 및 항당뇨 효과를 나타내었다.
The acid-solubilized finger root polysaccharide was prepared by using HCl solution of 0.05N, 1.0N, and 5N under the same conditions as in Example 2, and then the weight loss rate and fasting blood glucose reduction rate were measured by the methods of Experimental Example 1 and Experimental Example 2, respectively As shown in Table 2, anti-obesity and anti-diabetic effects were significantly exhibited.
감소율(%)weight
Decrease (%)
감소율(%)Fasting blood sugar
Decrease (%)
<< 실시예Example 10-13> 효소 가용성 10-13> Enzyme solubility 핑거루트Finger root 다당류의 분리 Separation of polysaccharides
상기 실시예 1에서 제조된 핑거루트 다당류 복합체 15g에 150 ml의 증류수를 가한 후 핑거루트 다당류 복합체에 대한 중량비로 상업용 가수분해 효소인 셀룰라제로서 셀루클라스트(Celluclast, Novo Nordisk, Denmark)를, 헤미셀룰라제로서 비스코자임(Viscozyme, Novo Nordisk, Denmark)을, 펙티나제로서 펙티넥스(Pectinex, Novo Nordisk, Denmark)를, 베타클루카나제로서 울트라플로(Ultraflo, Novo Nordisk, Denmark)를 1:0.01을 가한 후 효소의 반응조건에 따라 pH 4~6, 온도 40~60에서 6시간 교반한다. 상기 시료를 100에서 10분간 가열하여 효소를 불활성화 한 다음 6,500rpm에서 15분간 원심분리하여 다당류가 함유된 상등액을 획득한다. 상기에서 얻어진 추출물에 포함되어 있는 전분을 가수분해하기 위해 효소 최적 조건에서 -아밀라제(-amylase; Termamyl 120L, NOVO Nordisk A/S, Denmark)와 글루코아밀라제(glucoamylase; AMG 300L, NOVO Nordisk A/S, Denmark)를 처리한 후 중화하였다. 상기 여액을 (molecular weight) cut off(MWCO)가 1000인 막(membrane)을 이용하여 한외여과(thin channel ultrafiltration system, Amicon TCF-10; Amicon Co., U.S.A.)하였다. 한외 여과 후 분자량 1000 이상의 용액을 모아 동결건조함으로써 효소 가용성 핑거루트 다당류(enzyme soluble fingerroot polysaccharides)를 얻었고 수율은 표 3에 나타내었다.
After 150 ml of distilled water was added to 15 g of the finger root polysaccharide complex prepared in Example 1, cellulase (Celluclast, Novo Nordisk, Denmark) was used as a commercial hydrolysis enzyme as a weight ratio to the finger root polysaccharide complex, (Pectinex, Novo Nordisk, Denmark) as a pectinase and Ultraflo (Novo Nordisk, Denmark) as a betaclucanase in a ratio of 1: 0.01 as a cellulase (Viscozyme, Novo Nordisk, Denmark) And the mixture is stirred for 6 hours at a pH of 4 to 6 and a temperature of 40 to 60 according to the reaction conditions of the enzyme. The sample is heated at 100 for 10 minutes to inactivate the enzyme and centrifuged at 6,500 rpm for 15 minutes to obtain a supernatant containing the polysaccharide. In order to hydrolyze the starch contained in the extract obtained above, amylase (-amylase; Termamyl 120L, NOVO Nordisk A / S, Denmark) and glucoamylase (AMG 300L, NOVO Nordisk A / S, Denmark). The filtrate was subjected to ultrafiltration (Amicon TCF-10; Amicon Co., USA) using a membrane having a molecular weight cutoff (MWCO) of 1000. After ultrafiltration, solutions having a molecular weight of 1000 or more were collected and lyophilized to obtain enzyme soluble fingerroot polysaccharides. The yields are shown in Table 3.
<< 실험예Experimental Example 7-10> 동물모델에서 효소 가용성 7-10> Enzyme availability in animal models 핑거루트Finger root 다당류의 Polysaccharide 항비만Anti-obesity 효과 effect
상기 실시예 10-13에서 제조된 효소 가용성 핑거루트 다당류의 항비만 효과를 상기 실험예 1과 동일한 방법으로 실험한 결과 표 2에 나타낸 바와 같이 시험군의 체중 및 부고환 지방의 무게가 대조군에 비하여 유의적으로 감소하였다. 이러한 결과는 본 발명의 효소 가용성 핑거루트 다당류가 항비만 효과를 제공하는 것을 의미한다.
The anti-obesity effects of the enzyme-soluble finger root polysaccharides prepared in Examples 10-13 were tested in the same manner as in Experimental Example 1. As shown in Table 2, the weight of the test group and epididymal fat weight were significantly Respectively. These results indicate that the enzyme-soluble finger root polysaccharides of the present invention provide an anti-obesity effect.
감소율(%)weight
Decrease (%)
<< 실험예Experimental Example 11-14> 동물모델에서 효소 가용성 11-14> Enzyme availability in animal models 핑거루트Finger root 다당류의 Polysaccharide 항당뇨Anti-diabetic 효과 effect
상기 실시예 4-7의 효소 가용성 핑거루트 다당류의 항당뇨 효과를 상기 실험예 2과 동일한 방법으로 실험한 결과 표 5에 나타낸 바와 같이 시험군의 공복 혈당과 공복 인슐린이 대조군에 비하여 유의적으로 감소하였다. 이러한 결과는 본 발명의 효소 가용성 핑거루트 다당류가 항당뇨 효과를 제공하는 것을 의미한다.
The antidiabetic effect of the enzyme-soluble finger root polysaccharide of Example 4-7 was tested in the same manner as in Experimental Example 2. As shown in Table 5, fasting blood glucose and fasting insulin in the test group were significantly decreased Respectively. These results indicate that the enzyme-soluble finger root polysaccharides of the present invention provide an antidiabetic effect.
감소율(%)Fasting blood sugar
Decrease (%)
<< 실시예Example 14> 압출성형 가용성 14> Extrusion Moldability 핑거루트Finger root 다당류의 분리 Separation of polysaccharides
상기 실시예 1에서 제조된 핑거루트 다당류 복합체를 L/D비(length:diameter ratio) 20의 이축 압출반응기에 투입한 후 스크류 속도 250rpm, 시료투입속도 40kg/hr, 수분함량을 25%으로 유지하면서 압출 성형하였다. 상기 압출성형된 핑거루트 다당류 복합체 50g을 증류수 1L에 넣고 1시간 동안 교반한 후, 6,500에서 10분간 원심분리하였다. 원심분리 후 얻어진 상등액을 여과한 다음 4L의 이소프로판올(isopropanol)을 첨가하고 4시간 동안 방치하여 침전물을 획득하였다. 상기 침전물을 이소프로판올과 아세톤(acetone)으로 세척한 후 상온에서 건조시켜 압출성형 가용화 핑거루트 다당류(extrusion soluble fingerroot polysaccharides)를 제조하였다(제조수율 13.6%).
The finger root polysaccharide complex prepared in Example 1 was put into a biaxial extrusion reactor having an L / D ratio of 20, and then kept at a screw speed of 250 rpm, a sample feed rate of 40 kg / hr, and a water content of 25% Followed by extrusion molding. 50 g of the extruded finger root polysaccharide complex was added to 1 L of distilled water, stirred for 1 hour, and then centrifuged at 6,500 for 10 minutes. After centrifugation, the resulting supernatant was filtered, 4 L of isopropanol was added, and the mixture was allowed to stand for 4 hours to obtain a precipitate. The precipitate was washed with isopropanol and acetone, and then dried at room temperature to produce extrusion-soluble fingerroot polysaccharides (production yield: 13.6%).
<< 실험예Experimental Example 15> 동물모델에서 압출성형 가용성 15> Extrusion Moldability in Animal Models 핑거루트Finger root 다당류의 Polysaccharide 항비만Anti-obesity 효과 effect
상기 실시예 14에서 제조된 압출성형 가용성 핑거루트 다당류의 항당뇨 효과를 상기 실험예 1과 동일한 방법으로 실험한 결과 시험군의 체중 및 부고환 지방의 무게가 대조군에 비하여 각각 18.4% (p<0.01) 및 20.8% (p<0.05) 감소하였다. 이러한 결과는 본 발명의 압출성형 가용성 핑거루트 다당류가 체중 및 체지방 감소 효과를 제공하는 것을 의미한다.
The antidiabetic effect of the extruded soluble finger root polysaccharide prepared in Example 14 was 18.4% (p < 0.01) in weight and epididymal fat weight of the test group, And 20.8% (p < 0.05), respectively. These results indicate that the extruded soluble finger root polysaccharides of the present invention provide body weight and body fat reduction effects.
<< 실험예Experimental Example 16> 동물모델에서 압출성형 가용성 16> Extrusion Moldability in Animal Models 핑거루트Finger root 다당류의 Polysaccharide 항당뇨Anti-diabetic 효과 effect
상기 실시예 14에서 제조된 압출성형 가용성 핑거루트 다당류의 항비만 효과를 상기 실험예 2과 동일한 방법으로 실험한 결과 시험군의 공복 혈당과 공복 인슐린이 대조군에 비하여 각각 20.6% (p<0.01) 및 19.3% (p<0.05) 감소하였다. 이러한 결과는 본 발명의 압출성형 가용성 핑거루트 다당류가 항당뇨 효과를 제공하는 것을 의미한다.
The anti-obesity effect of the extruded soluble finger root polysaccharide prepared in Example 14 was tested in the same manner as in Experimental Example 2. As a result, fasting blood glucose and fasting insulin of the test group were 20.6% (p < 0.01) And decreased by 19.3% (p <0.05). These results indicate that the extruded soluble finger root polysaccharides of the present invention provide an antidiabetic effect.
상기 핑거루트 다당류는 우수한 항비만 및 항당뇨 효과가 있어, 항비만 및 항당뇨 식품 조성물또는 약학적 조성물을 제조 할 수 있으므로 산업상 이용가능성이 높다.
The finger root polysaccharide has an excellent anti-obesity and antidiabetic effect, and can be used for the production of an anti-obesity and antidiabetic food composition or a pharmaceutical composition.
Claims (10)
(S2) 상기 분말을 유기용매로 추출한 후에 여과 또는 원심분리하여 핑거루트 다당류 복합체(fingerroot polysaccharide complex)를 얻는 단계;
(S3) 상기 핑거루트 다당류 복합체를 가용화하여 핑거루트 다당류가 함유된 용액을 제조하는 단계;
(S4) 상기 핑거루트 다당류가 함유된 용액에 전분 가수분해효소를 가하여 전분을 제거하는 단계;
(S1) preparing a powder of a fingerroot;
(S2) extracting the powder with an organic solvent, followed by filtration or centrifugation to obtain a fingerroot polysaccharide complex;
(S3) solubilizing the finger root polysaccharide complex to prepare a solution containing finger root polysaccharides;
(S4) adding starch hydrolyzing enzyme to the solution containing the finger root polysaccharide to remove starch;
The method for producing a finger root polysaccharide according to claim 1, wherein the solubilization in step (S3) is carried out using an alkali, an acid, or a hydrolytic enzyme.
3. The method according to claim 2, wherein the alkali solution is 0.01 to 10 N NaOH.
3. The method of claim 2, wherein the acid solution is 0.01 to 10 N HCl.
The method for producing a finger root polysaccharide according to claim 2, wherein the hydrolytic enzyme is selected from the group consisting of cellulase, hemicellulase, pectinase, and beta-glucanase.
The method according to claim 1, wherein the solubilization in the step (S3) uses extrusion molding.
The method according to claim 1, wherein the step (S5) comprises removing the low-molecular component by dialysis or ultrafiltration.
A finger root polysaccharide obtained by the method according to any one of claims 1 to 6.
9. An anti-obesity and antidiabetic pharmaceutical composition comprising the polysaccharide of claim 8 as an active ingredient.
9. An anti-obesity and antidiabetic food composition comprising the polysaccharide of claim 8 as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140056099A KR102059078B1 (en) | 2014-05-12 | 2014-05-12 | Anti-obese and anti-diabetic composition comprising fingerroot polysaccharides |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140056099A KR102059078B1 (en) | 2014-05-12 | 2014-05-12 | Anti-obese and anti-diabetic composition comprising fingerroot polysaccharides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150129344A true KR20150129344A (en) | 2015-11-20 |
| KR102059078B1 KR102059078B1 (en) | 2019-12-24 |
Family
ID=54844052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140056099A KR102059078B1 (en) | 2014-05-12 | 2014-05-12 | Anti-obese and anti-diabetic composition comprising fingerroot polysaccharides |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102059078B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180033924A (en) * | 2016-09-27 | 2018-04-04 | 이상기 | Method of manufacturing noodles using fingerroot extract |
| KR20180087591A (en) | 2017-01-25 | 2018-08-02 | (주)나눔랩 | Method for feeling of fingerroot and manufactured goods thereof |
| KR20210008704A (en) * | 2019-07-15 | 2021-01-25 | 김창제 | Diet Snacks for Pets and Their Manufacturing Methods |
| KR20210053557A (en) * | 2019-11-04 | 2021-05-12 | 강원도 | Hot pepper paste composition comprising Poris cocos and method of manufacturing the same |
-
2014
- 2014-05-12 KR KR1020140056099A patent/KR102059078B1/en active IP Right Grant
Non-Patent Citations (2)
| Title |
|---|
| International Journal of Molecular Science, Vol. 13, pp. 994-1005 (2012.) * |
| Obesity and Metabolism, Vol. 13, pp. 584-593 (2011.) * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180033924A (en) * | 2016-09-27 | 2018-04-04 | 이상기 | Method of manufacturing noodles using fingerroot extract |
| KR20180087591A (en) | 2017-01-25 | 2018-08-02 | (주)나눔랩 | Method for feeling of fingerroot and manufactured goods thereof |
| KR20210008704A (en) * | 2019-07-15 | 2021-01-25 | 김창제 | Diet Snacks for Pets and Their Manufacturing Methods |
| KR20210053557A (en) * | 2019-11-04 | 2021-05-12 | 강원도 | Hot pepper paste composition comprising Poris cocos and method of manufacturing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102059078B1 (en) | 2019-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100497396C (en) | Dendrobium candidum polysaccharide extractive, medicine composition thereof and its preparation and use | |
| CN101357952B (en) | Polysaccharide MA from Mytilus coruscus with hypolipidemic activity and preparation method thereof | |
| EP3991742A1 (en) | Coronavirus therapeutic agent comprising elaeocarpus sylvestris extract as active ingredient | |
| CN103462025A (en) | Health food assisting in reducing blood fat and preparation method and application thereof | |
| KR102059078B1 (en) | Anti-obese and anti-diabetic composition comprising fingerroot polysaccharides | |
| CN103118689A (en) | Arctigenin-containing bardanae fructus extract and method for producing same | |
| KR100789362B1 (en) | Immunostimulating polysaccharides isolated from Curcuma xanthorrhiza and manufacturing method thereof | |
| JP6228250B2 (en) | Polysaccharide digestion inhibitor | |
| CN101444599B (en) | Corn silk extract and preparation method thereof and application thereof in preparing drugs for treating gout | |
| KR20150129343A (en) | Anti-obese composition comprising Java tumeric polysaccharides | |
| JP2007031302A (en) | Adiponectin production accelerator and metabolic syndrome preventive | |
| CN113116867B (en) | Composition for preventing and/or treating influenza | |
| KR20150115575A (en) | Anti-obese and anti-diabetic composition comprising Allium hookeri polysaccharides | |
| KR20150115576A (en) | Anti-obese and anti-diabetic composition comprising Allium hookeri polysaccharides | |
| CN105963330A (en) | Miracle fruit preparation and application thereof | |
| JP2010202569A (en) | Antiallergic and anti-inflammatory composition | |
| CN103906525A (en) | Application of albizzia chinensis extract in preparation of medicine for treatment of gastric ulcer | |
| JP2009298702A (en) | Oral administration composition | |
| CN101121662A (en) | Chlorogenic acid ester derivative, preparation method and application thereof in pharmaceutical preparation | |
| CN109700819A (en) | A kind of pharmaceutical composition of Weight-reducing and lipid-lowering and preparation method thereof and purposes | |
| JP2002104981A (en) | Method for producing guarana extract, remedy and prophylactic for liver function failure and tumor immunopotentiator containing the guarana extract as active ingredient, and functional food containing the guarana extract | |
| CN109700818B (en) | Medicinal composition for losing weight and reducing blood fat and preparation method and application thereof | |
| KR102176394B1 (en) | A composition for immune enhancement comprising taheebo extract | |
| CN107699599B (en) | Camel blood polypeptide with blood pressure and blood fat reducing effects | |
| JP2006241020A (en) | Immune system activating agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| N231 | Notification of change of applicant | ||
| N231 | Notification of change of applicant | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |